Product Certification&
    Enterprise Certification

  • Ms.Amy
    Tel: 86-755-23284190

  • Ms.Dany
    Tel: +86-755-23284190

  • Ms.Amy
    Tel: +86-755-23284190

  • Mr.Ajay
    Tel: (86-755)23284190

  • Ms.Cindy
    Tel: +(86-755)23284190

  • Mr.Alan
    Tel: +(86-755)23284190

  • Ms.Sunny
    Tel: 0086-755-23284190

  • Mobile:13798224190
  • Tel:86-755-23284190
  • Fax:
  • URL:
  • Province/state:GUANGDONG//HONGKONG
  • Street:B302,2 unit, Jin Lian Building, No. 134 Qianjin 2 Road, Taoyuan village, Xixiang Street, Baoan,Shenzhen,China
  • MaxCard:
Home > Products >  Alectinib 1256580-46-7/50Kg in stock

Alectinib 1256580-46-7/50Kg in stock CAS NO.1256580-46-7

  • FOB Price: USD 10 /Gram Get Latest Price
  • Min.Order: 1 Gram
  • Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram,Other
  • Available Specifications:


  • Product Details


  • CH5424802
  • Alectinib
  • API

Quick Details

  • ProName: Alectinib 1256580-46-7/50Kg in stock
  • CasNo: 1256580-46-7
  • Molecular Formula: C30H34N4O2
  • Appearance: white powder
  • Application: CH5424802/1256580-46-7/99%
  • DeliveryTime: prompt
  • PackAge: 1 gram/bag
  • Port: any port
  • ProductionCapacity: 1000 Gram/Day
  • Purity: 99%
  • Storage: keep away from heat,sparks and flames
  • Transportation: by air or by courier
  • LimitNum: 1 Gram


High purity with HPLC & NMR chart
99% purity with low price in stock
specilized in hard-to-find chemicals


Alectinib (marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
Approvals and indications
Approved in Japan in July 2014 for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer.
Alecensa was approved by the US FDA in December 2015 to treat patients with advanced ALK-positive NSCLC[clarification needed]whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori).
Clinical trials
In a Japanese trial, after approximately 2 years, 19.6% of patients had achieved a complete response, and the 2-yearprogression-free survival rate is 76%.In Feb 2016 the J-ALEX phase III study comparing alectinib with crizotinib was terminated early because an interim analysis showed that progression-free survival was longer with alectinib.


We are Tianyuan Pharm, we offer  XL765/1349796-36-6/99%.

CHINA TIANYUAN PHARMACEUTICAL CO.,LIMITED is a professional manufacturer specialized in the production and distribution of active pharmaceutical ingredients and intermediates. Our company has strong R&D ability and production experience to provide the customers new APIs. We specialize in developing innovative processes for the synthesis of a wide range of products. We also undertake custom synthesis and contract manufacturing.such as Tenofovir(PMPA TDF 147127-20-6/202138-50-9.

Factory product below API&Intermediates,if you are interest in,pls contact with me,we also have Lab,specifical in some hard synthesis.
Tofacitinib Citrate
Sorafenib Tosylate 475207-59-1
Ruxolitinib (INCB018424)
Bortezomib 179324-69-7
Etravirine have DMF
Raltegravir potassium have DMF
Tenofovir Disoproxil Fumarate(TDF) have DMF

Other products of this supplier

lookchemhot product CAS New CAS